Exelixis, Inc. — Form 10-Q Summary
Period note: The filing covers the quarter ended March 30, 2012 (presented in the statements as March 31, 2012), compared with the corresponding 2011 quarter. This differs from the request metadata’s “2011 Q1.”
Business context and reporting period
Exelixis is a biotechnology company developing small-molecule cancer therapies. It focused its proprietary research and development resources on cabozantinib (XL184); partnered programs remained a potential source of milestone and royalty revenue. The unaudited results cover three months.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $18.5 million | $35.9 million |
| Operating expenses | $40.8 million | $59.6 million |
| Operating loss | $22.3 million | $23.7 million |
| Net loss | $26.2 million | $27.5 million |
| Net loss per share, diluted | $0.18 | $0.24 |
| Cash used in operating activities | $15.0 million | $43.3 million |
- Revenue fell 48.5% year over year. Exelixis reported no product-sale revenue; revenue came from collaboration and license arrangements. The filing provides no gross-profit figure or meaningful product gross margin.
- Research and development expense was $33.1 million, down 27.6%; general and administrative expense was $7.9 million, down 14.1%. Restructuring was a $0.2 million credit, versus a $4.8 million charge in Q1 2011.
- At March 31, cash and cash equivalents were $70.5 million, marketable securities $173.0 million, long-term investments $84.5 million, and restricted cash and investments $4.2 million. The company reported $332.1 million in these resources in aggregate, including restricted funds; about $84.5 million of cash and securities was held as collateral under the Silicon Valley Bank agreement.
- Current assets were $250.0 million and current liabilities $87.5 million. Total liabilities were $280.3 million; debt book value, including the Deerfield financing, was approximately $182.1 million. Stockholders’ equity was $132.3 million.
- Cash and cash equivalents declined $3.8 million during the quarter. Investing activities used $52.3 million, principally reflecting net purchases of marketable securities; financing activities provided $63.5 million, mainly from a February stock offering that raised approximately $65.0 million net and issued 12.7 million shares.
Material changes versus the prior comparable period
- Revenue decreased primarily because Sanofi-related development and discovery collaboration revenues and the Bristol-Myers Squibb XL281 agreement no longer contributed as before. This was partly offset by $10.7 million of revenue recognized under the Merck PI3K-delta license.
- Lower R&D expense mainly reflected the transfer of XL147 and XL765 activities to Sanofi, the wind-down of the EXAM trial, and reduced headcount and related costs. COMET-2 activity and COMET-1 preparation partly offset these decreases.
- Operating cash use improved from the prior-year quarter, in part because of a $27.9 million reduction in other receivables and changes in collaboration-related cash receipts and deferred revenue.
- The company reported net income of $75.7 million for full-year 2011, primarily due to accelerated recognition of collaboration revenue upon agreement terminations; management cautioned that losses and negative operating cash flow were expected going forward.
Outlook, management commentary, risks, and unusual items
- Management expected available cash, investments, and anticipated funding from existing collaborators to support operations for at least 12 months after the May 3, 2012 filing date, but stated that future capital needs would be substantial and additional capital would be needed.
- Management expected to complete the rolling NDA submission for cabozantinib in medullary thyroid cancer in Q2 2012 and planned to initiate the COMET-1 prostate-cancer trial in Q2 2012. It described a potential commercial launch in the second half of 2012 as conditional on priority review and FDA approval. COMET-2 had begun in December 2011.
- The FDA had not agreed to a Special Protocol Assessment for COMET-2 and had raised concerns about trial blinding, the pain-response endpoint, safety, and the need for evidence of antitumor activity and survival benefit. Exelixis proceeded without an SPA; the filing notes that FDA approval and timing remained uncertain.
- Management cited clinical and regulatory failure or delay, manufacturing and supply constraints, competition, reimbursement and pricing pressure, dependence on collaborators, and the need for additional financing as key risks. Future equity or convertible financing could dilute shareholders.
- Debt and liquidity constraints include Deerfield convertible notes with annual $6.0 million interest and specified mandatory prepayments in 2013–2015, and an $80.0 million Silicon Valley Bank term loan due in a balloon payment in 2017. The bank agreement requires collateral deposits tied to outstanding obligations; covenant breaches could accelerate debt.
- Restructuring charges since 2010 totaled $42.7 million. The company expected approximately $1.7 million of additional facility-related charges through the end of 2017. Q1 2012 included a $0.2 million restructuring credit, partly related to asset-sale proceeds.
- Disclosure controls were reported effective, and the company reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the reporting-period mismatch in the request metadata: the filing is for Q1 2012, not Q1 2011.
- Track completion and FDA review of the cabozantinib medullary thyroid cancer NDA, including review priority, approval outcome, and launch timing.
- Monitor COMET-1 and COMET-2 trial progress, endpoint results, safety findings, and further FDA feedback.
- Reconcile reported $332.1 million of liquidity with restricted and bank-collateralized funds, ongoing cash use, and management’s runway statement.
- Review Deerfield repayment and conversion terms, Silicon Valley Bank collateral and covenants, and the potential dilution from future financing or debt settlement in shares.